Introduction
Chronic obstructive pulmonary disease (COPD) is an airways disorder, characterised by airflow obstruction (forced expiratory volume in 1 second [FEV 1 ] / forced vital capacity [FVC] <0.7) on spirometry, which lacks significant reversibility on appropriate testing. It affects an estimated 3 million people in the UK, with approximately 900,000 having received a formal diagnosis. 1 Symptoms typically consist of cough, dyspnoea and wheeze, which do not vary significantly over time, in contrast to asthma, where symptoms may differ over hours to days.
The predominant aetiological agent is cigarette smoking, with increasing recognition of alternative exposures, for example biomass fuel, as causative, even in never smokers.
Diagnosis requires a combination of suggestive history, examination, imaging and spirometry, where findings of FEV 1 /FVC <0.7, FEV 1 <80% predicted, are supportive.
Therapy is multifaceted including inhaled pharmacotherapy which is discussed below. Particular importance is also placed on smoking cessation and pulmonary rehabilitation programmes to halt further damage to lung tissue and maintain exercise performance. Flu vaccination is recommended to reduce infection risk.
The principle agents of inhaled therapy include short-acting beta-agonists (SABA, eg salbutamol), long-acting beta-agonists (LABA, eg formoterol), long-acting muscarinic antagonist (LAMA eg tiotropium) and inhaled corticosteroids (ICSs, eg fluticasone). Numerous combination devices containing two or three agents exist.
ABSTRACT Inhaled therapy: the historic approach and its problems
As recently as 2010, National Institute for Health and Care Excellence (NICE) guidelines advocated a spirometry-based approach to inhaled therapies where, in the presence of appropriate symptoms, ICS in combination with LABA was commenced in those with an FEV 1 <50%, with or without LAMA. This has led to a number of patients on 'triple therapy' of LABA/ ICS plus LAMA.
Adverse 
Inhaled therapy: the current approach
More recently, the international collaboration Global Initiative for Chronic Obstructive Lung Disease (GOLD) 3 has updated its treatment recommendations to reflect this. A symptom-based approach to severity stratification is recommended in favour of the previously used FEV 1 , acknowledging the weak correlation between FEV 1 , symptoms and impairment of health, and allowing for more individualised patient care. Once a diagnosis of COPD is confirmed, patients are stratified according to Fig 1 . Patients are placed into an ABCD category based on level of dyspnoea according to modified medical research council scale (mMRC, 0-1 or ≥2,) or COPD assessment test, (CAT, <10, ≥10) and frequency and severity of exacerbations, (0-1 per year with no hospital admission, or either ≥1 with hospital admission or ≥2).
Inhaled therapy is prescribed according to the severity score, as per Fig 2 . > Group A patients (low dyspnoea, low exacerbation frequency) are treated with a bronchodilator of the prescribers choosing. > Group B (low exacerbation frequency, high dyspnoea) are offered either LABA or LAMA as fi rst line, with a combination LABA/LAMA should dyspnoea persist.
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This demonstrated numerous benefits when using LABA/LAMA, relative to LABA/ICS. An 80 mL improvement at week 12 and week 24-26 trough FEV 1 was noted, although this was below the minimum clinically important difference (MCID) of 100 mL. A 44% increase in likelihood of achieving MCID was seen. Peak FEV 1 was also higher at 12 weeks, with a mean difference of 120 mL. However, this does not inform on changes to lung function over the longer term.
Rescue medication use was reduced at the end of the study period (12-26 weeks) by -0.18 puffs/day, (95% CI −0.28 to −0.07, p=0.001,) in the LABA/LAMA group.
LABA/LAMA demonstrated a significant reduction in annual rates of both moderate and severe exacerbations (relative risk [RR] 0.82, 95% CI 0.75-0.91, p<0.001.) Although both the two included studies used indacaterol/glycopyrronium, hence it was not possible to determine whether this was a class effect or specific to this combination. 
Inhaled therapy: a new approach -ICS vs LABA/LAMA

Inhaled therapy: a new approach -ICS withdrawal
An older meta-analysis of early trials looking at ICS withdrawal in those already established on it, noted methodological limitations such as lack of bias and quality assessment, and inconsistent definition and management of exacerbations, although reported a 1.11 (95% CI 0.84-1.46) times increase in likelihood of exacerbation in the following year in the ICS withdrawal group, and overall concluded no evidence for clinically important deterioration following ICS withdrawal.
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A more recent meta-analysis concluded no significant increase in exacerbation rates post withdrawal, athough a clinically important increase in risk of severe exacerbation was detected. 8 Decline in FEV 1 (-30mL) and SGRQ (+1.24 points) was noted, although these were both below the MCID. Included in the above meta-analysis was the 12-month doubleblind WISDOM study. 9 Patients with severe or very severe COPD, who had experienced at least one exacerbation in the previous year were included. It compared continuation of triple therapy following a 6-week run-in period, versus a stepwise reduction to eventual discontinuation of ICS, and demonstrated non-inferiority (HR 1.06; 95% CI 0.94-1.19 -pre-specified non-inferiority criterion of 95% CI 1.20) with regards to first moderate or severe exacerbation. Note was made of a reduction in FEV 1 in the ICS withdrawal group at 18 weeks (when ICS withdrawal was complete) and at the end of the 52-week study period, although this was not felt to be clinically significant as it was below the MCID.
Contradicting these findings, however, the shorter 26-week INSTEAD trial, which compared switching from ICS/LABA to LABA alone, in moderate COPD patients who had experienced no exacerbations in the previous year demonstrated just 9 mL (95% CI -45-26 mL) difference between the two groups. 10 There was no statistical difference in exacerbation rates. In the CRYSTAL study, patients were randomised to direct switch to LABA/LAMA, or continuation of current therapy. 11 Compared to the LABA/ICS group, a 71 mL improvement in trough FEV 1 was noted, with significantly more patients reaching the MCID. However, this was an open-label study, with a duration of just 12 weeks, so conclusions regarding the impact on lung function over the longer term could not be drawn.
Eosinophilia
Accepting the limitations of these studies, the above demonstrates that ICS withdrawal is safe in terms of effects on exacerbation rates and lung function; however, one caveat to withdrawal relates to those patients with an eosinophilic phenotype. Post-hoc analysis 12 of data from the aforementioned WISDOM study demonstrated that exacerbation rates in the ICS withdrawal group was higher for those with higher peripheral eosinophil counts, 2% or greater (RR Post-hoc analysis of the 48-week randomised double-blind FORWARD study divided patients into quartiles based on baseline eosinophil count.
14 While exacerbation rates among patients receiving ICS were similar across the quartiles, within the highest quartile (≥279.8/μl) a 46% reduction in exacerbation rate was seen in those using ICS. A prospective population-based study in Copenhagen examined the relationship between baseline eosinophil count and COPD exacerbations and demonstrated that eosinophil levels above 0.34 × 10 9 cells/L were associated with a 1.76-fold increased risk of severe exacerbations (95% CI 1.56-1.99). 15 However, contrary to the above, post-hoc analysis of FLAME data showed that LABA/LAMA was superior to ICS/LAMA for the prevention of exacerbations, with no relationship demonstrated between exacerbation frequency and eosinophil count. 16 Higher rates of pneumonia were noted in the ICS/LABA group regardless of eosinophils. The IMPACT study demonstrated fewer exacerbations in those on triple therapy versus LABA/LAMA, although interestingly also versus those on ICS/LABA, regardless of eosinophil count. 6 A greater reduction in exacerbation rate was noted, however, in those with an eosinophil count greater than 150 cells/μL.
There is no clear consensus regarding cut-off values for eosinophils to be used to predict COPD exacerbations, or indeed whether eosinophil counts can be used in this way at all. It may, however, be reasonable to consider patients with an eosinophilia, together with a history of recurrent exacerbations, to be at increased risk of future exacerbations, and so continue ICS in this patient group.
Method of withdrawal
With regards to method of withdrawal -sudden stop versus gradual reduction, while the WISDOM study used a gradual reduction in ICS dose, additional studies have adopted a sudden discontinuation approach. There is no strong evidence to support gradual reduction, 17 and a direct switch from LABA/ICS to LABA/ LAMA can be made.
Conclusion
We have shown that ICS use is associated with an increased risk of pneumonia, especially when using fluticasone, and that LABA/ LAMA as an alternative is safe and effective across a range of outcome measures. ICS use in the management of COPD should now be regarded not as first line, but more of an 'if all else fails' treatment, in those who continue to exacerbate despite using LABA/LAMA.
A stepwise approach could be considered: as LAMA as first line, followed by combination LABA/LAMA should dyspnoea or exacerbation frequency not be satisfactorily controlled, and finally LABA/LAMA/ICS reserved for only a select group of patients troubled by recurrent exacerbations despite dual bronchodilators.
In those already established on LABA/ICS, direct withdrawal of ICS and switch to LABA/LAMA can be undertaken. Care should be taken when considering ICS withdrawal in patients who suffer frequent exacerbations, especially those who have a raised peripheral eosinophil count, although cut-off levels are not clear, and the relationship between eosinophilia and exacerbation risk remains to be elucidated. ■
